Last Update: Nov 12, 2026
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
ClinicalTrials.gov Identifier:
Novartis Reference Number:CDAK539A12001B
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients). The study will collect and monitor ongoing efficacy information with regard to disease and survival status, as well as safety information with regard to AEs, including SAEs and AEs of special interest (AESI).

Patients are eligible to continue pelabresib treatment as long as the regimen is tolerated, and the patient does not meet any of the discontinuation criteria.

Patients who have previously received pelabresib alone or pelabresib in combination with ruxolitinib or ruxolitinib alone will continue to receive the same regimen as administered in the parent study.

There will be an eligibility check period of up to 28 days for this extension study. Patients who fulfill the inclusion and exclusion criteria are eligible for the study. After the patient willingly provides consent, eligibility will be assessed by the investigator and treatment with pelabresib can be started at the same dose and dosing schedule that was applied in the parent study in the last cycle prior to EOT unless there is need for dose adjustment due to toxicity.

A patient is considered to have completed the study after completion of all visits as defined in the Schedule of Assessments (SoA) as per protocol, including the Safety Follow-up visit and Survival Follow-up.

The Safety Follow-up period is the interval between the EOT visit and the scheduled Safety Follow-up visit, which should occur 30 days (±3 days) after the last dose of pelabresib. For patients who switch from investigational pelabresib to commercial pelabresib treatment, the Safety Follow-up period is the time from the last dose of investigational pelabresib until the first dose of commercial pelabresib. The treatment start date with commercial pelabresib will be considered the date of "early Safety Follow-up termination." All patients will be followed for AEs and SAEs for 30 days (±3 days) following the last dose of pelabresib on the extension study or until the initiation of a new anticancer therapy, whichever occurs first.

Reasonable efforts should be made to have the patient return for the Safety Follow-up visit and review any AEs that may occur during this period. If the patient cannot return to the site for the Safety Follow-up visit, then the patient should be contacted by telephone for assessment of AEs.

The end of study will occur when all parent studies have been closed with no further patients expected to be enrolled into the extension study, and all patients are either discontinued or study treatment becomes commercially available and reimbursed, or an alternate access program becomes available, whichever comes first. Prior to study completion, all patients should.have completed the Safety Follow-up visit or have been designated as lost to follow-up, died, or have withdrawn consent, whichever comes first. The sponsor reserves the right to close a study site or terminate the study at any time for any reason at the sole discretion of the sponsor.

Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Phase3
Recruiting
50
Aug 13, 2024
Dec 31, 2029
All
18 Years - (Adult, Older Adult)

Interventions

Drug

Pelabresib

Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Drug

Ruxolitinib

Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

Eligibility Criteria

Inclusion Criteria:

* Able to provide signed informed consent, agreeing to all protocol and ICF requirements.
* At least 18 years old and legally able to consent in the study's jurisdiction.
* Previously enrolled and currently receiving pelabresib in combination with ruxolitinib or ruxolitinib alone in a parent study.
* Demonstrating clinical benefit from pelabresib and/or ruxolitinib, as judged by the investigator.
* Willing and able to follow all study visits, treatments, and procedures.
* Agree to avoid pregnancy or fathering children:

* Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.
* Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.
* Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.

Note: Women with amenorrhea due to chemo/radiotherapy are considered WOCBP and must use contraception.

Additional Inclusion Criteria control (placebo + ruxolitinib) group requiring pelabresib combination treatment:

* On a stable dose of ruxolitinib for ≥8 weeks
* Has adequate bone marrow and organ function as defined by the following local laboratory values:

* ANC ≥ 1 × 10\^9/L in the absence of growth factors for the previous 4 weeks
* Platelet count ≥ 75 × 10\^9/L in the absence of growth factors or platelet transfusions during previous 4 weeks
* Peripheral blood blast count \< 5%
* AST and/or ALT ≤ 2.5 × ULN of the local reference interval (≤ 5 × if the elevation can be ascribed to hepatic MF involvement, e.g., presence of hepatomegaly)
* Serum direct bilirubin \< 2.0 × ULN of the local reference interval
* Calculated or measured CrCl of ≥ 45 mL/min
* Does not have any other concurrent medical condition that in the opinion of the investigator could compromise participation in the study

Exclusion Criteria:

* Legally institutionalized or under judicial protection.
* Enrolled in another interventional clinical trial (excluding the parent study).
* History of hypersensitivity to pelabresib, its excipients, or similar drugs.
* Significant gastrointestinal issues (e.g., active IBD, unresolved nausea/vomiting/diarrhea \> Grade 1) that may affect drug absorption.
* Any medical condition deemed unsuitable by the investigator.
* Uncontrolled illness or condition that may compromise safety or protocol compliance.
* Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
* Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
* Used strong CYP3A4 inhibitors/inducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.
* Received immunosuppressive agents with systemic activity (\>10 mg QD prednisone or equivalent) less than 4 weeks before the first dose of study drug in the extension study. Participants who received topical, nasal, intra-articular, inhaled, and other forms of corticosteroids without systemic activity are eligible
* Received a live vaccination within 30 days prior to the first dose of study drug in the extension study, except for COVID-19 vaccination
* Female participants who are pregnant, breastfeeding, or not using required contraception.
* Male participants who do not agree to use contraception or refrain from sperm donation as specified.
* Unwilling or unable to comply with the study protocol.

Additional Exclusion Criterion for participants receiving ruxolitinib only treatment

• Local access to commercially available and reimbursed ruxolitinib.

Novartis Investigative Site

Recruiting

Bruges,8000,Belgium

Novartis Investigative Site

Recruiting

Antwerp,2030,Belgium

Novartis Investigative Site

Recruiting

Novara,28100,Italy

Novartis Investigative Site

Recruiting

Varese,VA,21100,Italy

Novartis Investigative Site

Recruiting

Florence,FI,50134,Italy

Novartis Investigative Site

Recruiting

Amsterdam,1081,Netherlands

Novartis Investigative Site

Recruiting

London,Se1 7eh,United Kingdom

Novartis Investigative Site

Recruiting

Glasgow,G12 0yn,United Kingdom

Novartis Investigative Site

Recruiting

Cardiff,Cf14 4xw,United Kingdom

Mt Sinai Medical Center

Recruiting

New York,New York,10029-6574,United States

Carly Sullivan
Marina Kremyanskaya

University of California LA

Recruiting

Los Angeles,California,90095,United States

Gary Schiller
Nicole Alimi NP

New York Presbyterian Hospital

Recruiting

New York,New York,10021,United States

Penina Stewart
Joseph Scandura

Uni Of Michigan Health System

Recruiting

Ann Arbor,Michigan,48109,United States

Moshe Talpaz
Hayley Demchak

Northwestern University

Recruiting

Chicago,Illinois,60611,United States

Gabby Perea
Brady L Stein

Mayo Clinic Jacksonville

Recruiting

Jacksonville,Florida,32224,United States

Tina Kothare
Candido Rivera

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals